WSC domain sialate O sulfotransferase 2Genealiases: []
Q-omics provides the consensus-scored WSCD2 profile across patient tissues and cancer cell-line models. WSCD2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, WSCD2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, WSCD2 RNA expression shows 20,190 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where WSCD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WSCD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WSCD2 survival associations across molecular data types. WSCD2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WSCD2 RNA expression–survival associations across cancer types. High WSCD2 expression shows unfavorable associations in KIRP, but favorable associations in KIRC, SKCM, LUAD, LGG and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for WSCD2 RNA expression.
This table summarizes WSCD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for WSCD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WSCD2 shows lower tumor expression in THCA, KIRP, KIRC, COAD, UCEC and KICH. The THCA box plot shows higher WSCD2 RNA expression in normal versus tumor tissue (log2 FC = −5.747, t-test p < 0.001).
This table shows molecular features associated with WSCD2 in patient tissues and cancer cell lines. In patient samples, WSCD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, WSCD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
